Physician profile
Ardy C Wright
NPI 1558455030
$3,992.84
in general payments reported to CMS, 2019-2025
30 companies · $97.01 in 2025
The $97.01 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,825 · 2020: $429 · 2021: $677 · 2022: $419 · 2023: $271 · 2024: $275 · 2025: $97.01.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $643.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $642.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $667.36 | 2019-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Lilly USA, LLC | $534.03 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $447.22 | 2019-2021 | |
| Pfizer INC. | $233.09 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $213.67 | 2019 | |
| Allergan, INC. | $205.28 | 2019 | |
| Novo Nordisk INC | $196.10 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $181.06 | 2019-2022 | |
| Amgen INC. | $165.24 | 2019-2024 | Evenity, Prolia |
| Astellas Pharma US INC | $163.48 | 2019-2024 | Veozah |
| Astrazeneca Pharmaceuticals Lp | $127.19 | 2019-2024 | Airsupra |
| Amarin Pharma, INC. | $122.97 | 2019 | |
| Sanofi-Aventis U.S. LLC | $122.85 | 2019 | |
| Sunovion Pharmaceuticals INC. | $118.54 | 2019 | |
| Seqirus USA INC | $82.55 | 2019-2024 | Flucelvax, Fluad |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $72.52 | 2023-2024 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $71.51 | 2022-2025 | |
| Abbvie INC. | $71.05 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.47 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $24.06 | 2023 | Rexulti |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $19.52 | 2024 | |
| Esperion Therapeutics, INC. | $16.05 | 2020 | |
| Eisai INC. | $15.25 | 2021 | |
| Hologic Sales and Service, LLC | $15.02 | 2021 | |
| Avanir Pharmaceuticals, INC. | $14.67 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $14.45 | 2021 | |
| Merck Sharp & Dohme LLC | $11.94 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $11.90 | 2020 | |
| Genentech USA, INC. | $11.67 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $11.13 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ardy Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.